At Pall, we understand the uphill battle you are facing to deliver a robust, reproducible and scalable gene therapy viral vector process. We have the proven scalable technology, end-to-end integrated platforms, knowledge and services to help you get your gene therapy to market. Work with us to increase your speed to commercialization or to improve process productivity and deliver therapies to transform lives.

Helaina is the first company leveraging precision fermentation to make human proteins with bioactive properties, previously only available in human milk. Helaina is utilizing bioactive proteins to deliver the first humanized infant formula capable of the same immunity benefits (antiviral, antibacterial, and antifungal) as breast milk. There are hundreds of applications for this technology outside of infant formula, and using fermentation to recreate bioactive ingredients is a sustainable and targeted way to deliver novel functional ingredients to all foods.

Phage therapy doesn’t work… yet. Since almost the moment of their discovery, phage has been touted as an antibacterial treatment, but after 100+ years we still don’t have a successful, generalizable phage therapy. At Felix, we are combining the awesome power of synthetic biology, machine learning, and evolutionary biology to finally crack the phage code.

Synbio has a software problem. Many companies aspire to be the, “AWS”, of synthetic biology but they’re all missing a massive critical piece of infrastructure. The core software and libraries to do it. AWS had Linux. They had Git. They had a vast bazaar of open source packages, databases, and languages to help them build their, “cloud”, but what does synbio have? Until now? Nothing but a few, old, abandoned python packages. That’s why I made Poly - the world’s most modern, open source, software library for engineering organisms. Already the most advanced synbio software on the open web, come learn how Poly can help your software team shine.

NEED DESCRIPTION

R2DIO ("radio") makes it easier to resolve signals and control noise by making every aspect of interdisciplinary R&D more traceable, more analyzable and more improvable. Our R2DIO Programs enable your team to capture more data with less work. Our R2DIO Tower makes R&D data accessible as SQL-queryable tables that are ready for visualization and rich statistical analysis.

Discussion will focus on Wild Earth's immediate goals to advance the future of pet food in the plant-based and cell-based food space, including a brief look at our longevity research.

The answer to our waste and pollution challenges lies in nature. In nature, nothing is wasted, and we believe this principle can—and must—be applied to industry as well. Nature knows how to heal itself, but it may take hundreds or thousands of years to accomplish this unaided. We must act sooner. We can learn from nature and bring a new level of performance to its potential. Taking nature’s lead, advancing its evolution and combining it with existing proven treatment technologies and deployment models will enable the ability to redeem waste, liberate natural resources, and permanently remove harmful pollutants.

Implantable BCIs are transitioning from moonshot demonstrations to tangible tools that restore lost function and address a variety of neurological disorders. With it, the focus of scientific discovery needs to be driven by the practical challenges posed by real life use. What is a realistic technological trajectory today - and what is possible tomorrow? What recent advances will enable widespread use of BCI for restoration? What objectives and areas should public and private investments focus on?

Building a future of abundance will require a paradigm shift in how we assemble molecular products from basic building blocks as well as how we disassemble toxic pollutants in our environment. Aether is building an intelligent enzyme engineering platform to tackle these challenges by generating datasets of unprecedented size, and designing novel enzymes to catalyze reactions that are impossible today. This will enable the next generation of molecular products, and to detoxification our environment.

Climate change is the biggest challenge to solve this decade. Concrete is the second most consumed substance on the planet following water. The production of Portland cement, the active ingredient in concrete- is responsible for 8% of global CO2 emissions due to the firing of limestone to get calcium. Using blueprints from nature, Biomason creates cement in a radically different way eliminating the need to emit carbon during production—curing the root disease, rather than treating the symptoms. Biomason is the only company in the world employing biology to produce cement, and our goal is to eliminate 25% of the concrete industry’s global carbon emissions by 2030.

Understanding and harnessing the power of microbiomes—both individual and ecological—holds the key to tackling many of the worlds’ Grand Challenges. But effectively implementing these solutions requires a robust data fabric and the application of network science. By providing a microbiome innovation ecosystem, Eagle Genomics is enabling companies to drive sustainable innovation across food, personal care, agritech, and healthcare.

People love glowing plants, but this has been mere fantasy until now. Light Bio has the only technology to make glowing plants a reality. Ornamental plants that emit living light are now being developed for use in homes and gardens. With their soft illumination, these plants bring forth a magical experience. And they are here at SynBioBeta to provide the world’s first exhibit of live glowing plants.

The vaccine race against COVID-19 is both a sprint and a marathon. Injected vaccines successfully completed the sprint and are preventing severe disease, but they cannot block transmission. This talk will discuss why the next vaccine for COVID-19 must be intranasal and why it also should be live attenuated and recombinant.

Energy Transition is already happening and has led to heavy industries (Chemicals, Oil & Gas, Mining, etc.) accelerating their decarbonization efforts to maintain the support of ESG investors. The great challenge is how to how to balance sustainability and profitability. Synthetic Biology is a viable solution for creating a double bottom line.

As enterprises increasingly embrace biology-driven solutions to traditionally nonbiological problems, development teams are faced with novel and highly complex technical challenges. Breaking new ground in these areas requires a level of consilience, for scientists have the necessary interdisciplinary training to draw from deep expertise in chemistry, computer science, engineering, and more. Synbio is at the precipice of unprecedented breakthroughs in countless sectors of industry and companies are hungry for talented scientists that will drive cross-cutting teams.

There is a myriad of ways to approach automation and particularly synthetic biology, and many have merit. What is presented here is a modular approach that can support considerable productivity quickly, yet grow into a fully integrated system if that is desired and is warranted. Workcells that automate the synthetic biology building blocks of transformation, growth and selection, extraction and purification, quantitation are often separate workflows that allow a break point of islands or silos of automation. However, workcells that are islands or silos can themselves cause productivity issues and full automation is often the end goal.

A non-conventional yeast strain was developed to produce flavor and fragrance compound through synthetic biology, metabolic analysis, and fermentation optimization.